In Brief: Novartis' Transderm Scop
This article was originally published in The Tan Sheet
Executive Summary
Novartis' Transderm Scop: Rx scopolamine motion sickness transdermal patch being reintroduced through direct-mail campaigns to health care professionals in September and consumers in November. Transderm Scop originally was marketed as an OTC product. In an attempt to position Transderm Scop against available OTC motion sickness alternatives such as Pharmacia & Upjohn's Dramamine, Novartis is relying on lower pricing and insurance coverage of the Rx product. The scopolamine 1.5 mg patch will begin shipping Oct. 1 and reach pharmacy shelves in mid-November. The product was withdrawn from the market in August 1994 due to manufacturing problems. Novartis received FDA approval to modify the manufacturing process in October. The brand is being remarketed under the company's Consumer Health division...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning